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A Fibrose Quística é a doença recessiva autossómica letal mais comum na 
população caucasiana. É caracterizada do ponto de vista clínico por um declínio rápido 
na função pulmonar, com obstrução das vias aéreas devido à ineficaz remoção de 
muco e consequentes infecções bacterianas recorrentes. Estas alterações estão 
associadas desde muito precocemente a um ambiente de hiperinflamação, que 
exacerba os processos de remodelação do tecido pulmonar e acaba por culminar na 
fibrose dos tecidos e perda da sua função. Além deste fenótipo respiratório, os 
pacientes apresentam ainda problemas digestivos graves, nomeadamente a nível 
pancreático, intestinal e hepático, e são inférteis no caso dos homens e de uma 
elevada percentagem das mulheres.  
A fibrose quística é causada por mutações no gene CFTR (do inglês Cystic 
Fibrosis Transmembrane Conductance Regulator) que codifica para uma proteína com 
o mesmo nome. Neste momento, conhecem-se cerca de 1930 mutações causadoras 
da doença, sendo a mais comum a delecção de três nucleótidos que correspondem ao 
resíduo de fenilalanina na posição 508 da proteína. Esta mutação está presente em 
cerca de 90% dos pacientes.  
Esta proteína é expressa em células epiteliais de vários tecidos, e além de 
funcionar como um canal de cloreto e outros aniões na membrana apical dessas 
células, é também responsável por regular outros canais e transportadores, tendo um 
impacto global no transporte iónico epitelial. A fosforilação pela proteína cinase A em 
resposta a aumento dos níveis de AMP cíclico é considerada o principal mecanismo 
responsável pela abertura do canal. 
Ao ser sintetizada, a CFTR é inserida co-traducionalmente na membrana do 
retículo endoplasmático, onde adquire a sua conformação nativa com o auxílio de 
vários chaperones aí presentes e sofre uma glicosilação inicial. Do retículo 
endoplasmático, é transportada para o Golgi, onde os seus resíduos glicídicos são 
processados até atingir uma forma madura, que é transportada em vesículas para a 
membrana plasmática, onde exerce a sua função. Uma vez na membrana, a CFTR é 
endocitada e segue uma de duas vias: ou é reciclada de volta para a membrana ou é 
enviada para degradação no lisossoma. O balanço destes processos determina a 
quantidade de proteína presente na membrana, e como tal são relevantes para a 
compreensão do defeito molecular que origina a doença..  
As interacções que a CFTR estabelece com outras proteínas ao longo deste 
trajecto são determinantes para que a proteína consiga exercer convenientemente a 
sua função. Recentemente, a pequena GTPase Rap1A foi identificada como 
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potencialmente interagindo com a CFTR. O objectivo deste trabalho consistiu na 
validação dessa interacção e no estabelecimento de um sistema experimental que 
permitisse avaliar o impacto da Rap1A na biogénese, tráfego e função da CFTR. 
A Rap1A é uma pequena GTPase da família Ras que está activa quando ligada a 
GTP e inactiva quando ligada a GDP. A interconversão destas duas formas é auxiliada 
por proteínas reguladoras chamadas GEFs (activadores) e GAPs (inactivadores), que 
respondem a uma variedade de estímulos intra e extracelulares. Quando activa, a 
Rap1A induz alterações conformacionais em determinadas proteínas alvo, envolvidas 
na regulação da adesão à matriz extracelular e célula-célula, dinâmica do 
citoesqueleto e polarização celular, alterando a sua função. 
O primeiro passo do trabalho foi avaliar a expressão da Rap1A no tecido mais 
relevante do ponto de vista clínico, o pulmão. Para isto, realizaram-se experiências de 
Western Blot a partir de culturas primárias de células epiteliais dos brônquios de 
indíviduos saudáveis e de uma linha celular do epitélio brônquico de pacientes com 
fibrose quística (CFBE) que sobreexpressa CFTR. Observou-se em ambos os tipos 
celulares expressão da proteína. 
A estratégia escolhida para validar a interacção entre a CFTR e a Rap1A foi tentar 
co-imunoprecipitar ambas as proteínas. No entanto, não foi possível validar esta 
associação, tendo sido unicamente observada uma possível colocalização por ensaios 
de imunofluorescência. 
De seguida, foram produzidos com sucesso plasmídeos para expressão da 
Rap1A wt em fusão com GFP, bem como de um mutante constitutivamente activo e 
um dominante negativo. O protocolo de transfecção de células CFBE com estes 
plasmídeos e com siRNAs foi optimizado, embora as eficiências de transfecção 
atingidas tenham sido modestas. A expressão dos constructos fluorescentes foi 
analisada por Western Blot e revelou um problema de folding e/ou processamento, 
provavelmente decorrente da fusão com a GFP. A actividade dos constructos com 
Rap1A foi também avaliada com um ensaio de actividade específico. Observou-se que 
o mutante dominante negativo apresentava uma actividade igual ou superior à do 
constructo wt, enquanto o constitutivamente activo apresentava uma actividade igual 
ou inferior, o que levou a abandonar ambos estes mutantes. Estas discrepâncias em 
relação à literatura devem-se provavelmente à marcação com GFP. Em nenhuma 
destas experiências se observaram alterações na quantidade de CFTR total ou 
madura. O facto de não se ter observado um efeito pode ter sido devido à baixa 
eficiência de transfecção obtida, à baixa quantidade de proteína com o 
folding/processamento correctos ou devido a uma ausência de efeito.  
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Finalmente, recorreu-se a câmaras de Ussing para analisar a função da CFTR em 
monocamadas polarizadas de células CFBE transfectadas com siRNA contra a Rap1A 
ou siRNA scrambled. Não se observaram diferenças na corrente transepitelial induzida 
pelo tratamento com forscolina (um composto que faz aumentar os níveis de AMP 
cíclico na célula, activando a CFTR) ou com genisteína (um potenciador específico da 
CFTR que maximiza a abertura do canal) em células tratadas com siRNA contra a Rap 
e tratadas com siRNA scrambled. Posteriormente, analisando por Western Blot a 
expressão de Rap1A nestas células, concluiu-se que a transfecção foi pouco eficiente, 
o que justifica a ausência de efeito. 
De uma forma geral, houve dois factores limitantes neste trabalho: o facto de, 
apesar de um longo processo de optimização, as eficiências de transfecção 
continuarem bastante modestas, e o facto de o sistema de expressão utilizado ser de 
difícil utilização.  
As observações mais significativas resultantes deste trabalho são: 
- Tanto em culturas primárias de células epiteliais humanas dos brônquios e em 
células CFBE41o- observa-se expressão endógena de Rap1A e Epac.  
- O padrão de expressão dos factores Epac em células CFBE altera-se quando as 
células são polarizadas.  
- Rap1A é expressa abundantemente nas junções célula-célula no epitélio 
respiratório, onde co-localiza com a E-caderina. 
- A Rap1A parece co-localizar com a CFTR em células do epitélio respiratório 
polarizadas. 
- A quantidade total de CFTR e a quantidade da forma madura (banda C) estão 






CFTR, the protein whose malfunction causes cystic fibrosis, is a chloride channel 
expressed in the apical membrane of epithelial cells. CFTR undergoes a long journey 
in the cell, since it is translated in association with the endoplasmic reticulum until its 
degradation, throughout which it interacts with numerous proteins. One of these was 
recently identified as Rap1A, a small GTPase that regulates cell-cell and cell-matrix 
adhesion, cell polarity and cytoskeleton dynamics. The aim of this work was to validate 
the interaction between CFTR and Rap1A and evaluate the impact of this small 
GTPase on CFTR biogenesis, trafficking and function. 
Rap1A expression was observed by Western blot in primary cultures of human 
bronchial epithelial cells and in the CFBE cell line. Plasmids encoding for several 
variants of GFP-tagged Rap1A were generated. Transfection with these or with siRNAs 
was optimized, although only sub-optimal efficiencies were achieved. Expression of 
Rap1A constructs was analysed by Western Blot, revealing a folding and/or processing 
defect for most constructs. Rap1A activity assays showed that the constitutively active 
mutant didn’t have higher activation levels than the wt construct, whereas the dominant 
negative had more activity than the wt construct, suggesting that the GFP-tagged 
constructs were not the most appropriate for this kind of study. No effects on CFTR 
were observed with Rap1A upregulation, possibly because of the low transfection 
efficiencies.  
Finally, CFTR function upon knockdown of Rap1A was analyzed in Ussing 
chambers. However, only a minor trend of decrease of CFTR function was observed 
for Rap1A siRNA transfected samples.  
Although suggestive of the need of a different experimental system, the results 
evidenced that: 
- Lung epithelial cells have endogenous expression of Rap1A. 
- The band pattern for Epac changed when CFBE cells were polarized;  
- Rap1A appears to be enriched in cell-cell junctions, where it co-localizes with E-
cadherin;  
- Rap1A and CFTR seem to overlap;  
- There seems to be a positive correlation between Rap1A levels and both total 
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1.1 Cystic Fibrosis - Overview 
Cystic Fibrosis (CF) is the most common lethal autosomic recessive disorder in the 
Caucasian population. It affects 1 in 2500 to 6000 live births and has a carrier 
frequency of 1 in 25 to 40 individuals. The disease frequency is variable among 
different ethnic groups, being highest in Northeastern Europe and quite rare among 
Oriental populations (1:90,000)1.  
It was first described in 1938 as a disorder of its own right by Anderson and 
colleagues, who also came to find that it had a recessive autossomal pattern of 
inheritance. At the time of its discovery as a disease in its own right, cystic fibrosis was 
described as a digestive disorder, since the first detectable symptoms were intestinal 
obstruction in newborns and malnutrition in infants, and was associated with a 
progressive fibrosis of the pancreatic tissue. Because infants died at a very young age, 
these were the only symptoms that were noticeable. As the digestive problems in 
newborns and children were gradually overcome with the advances in healthcare, 
problems in the respiratory tract became the major cause for morbidity and mortality.  
In 1953, an excess of salt in the sweat of patients was identified, which was later 
attributed to a defect in chloride transport in the sweat glands. This defective chloride 
transport was also detected in the lung, pancreas and intestinal epithelium, the most 
affected tissues1. In 1989, the gene responsible for the disease was identified using a 
positional cloning strategy and cautiously named cystic fibrosis transmembrane 
conductance regulator (CFTR). This gene encodes for a cAMP-regulated chloride 
channel expressed in a number of epithelial tissues. It was found to harbour mutations 
in all CF patients analysed, the most common of which being a deletion of three 
nucleotides encoding for a phenylalanine in position 508 in the protein (∆F508, or 
F508del as it is most commonly termed now)2. This mutation is present in about 90% of 
all patients, and represents only one of the 1930 mutations in the CF gene described at 
the time this work was written3.  
Even though CF research has gone a long way since then, therapies targeting the 
molecular basis are only now starting to appear and reach the patients. This has only 
been possible thanks to international, concerted effort in understanding the molecular 
mechanisms governing CFTR biogenesis and function in health and disease, which will 
be discussed in this Introduction. 
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1.2 Clinical features of Cystic Fibrosis and therapeutics 
Clinical features of CF are dominated by involvement of the respiratory tract, with 
obstruction of the airways by thick, dehydrated airway mucus that prevents proper 
mucocilliary clearance. This leads to recurring bacterial infections, especially with 
Pseudomonas aeruginosa and Staphylococcus aureus species. A hyperinflammation 
environment is generated in the lungs of patients from a very early age, exacerbating 
tissue remodelling processes and fibrosis4. This degradation of the lung tissue and loss 
of its function is the main cause of morbidity and mortality among CF patients. The 
involvement of the gastrointestinal tract is also common, with 85% of the patients 
presenting pancreatic insufficiency as a result of the obstruction of the pancreatic 
ducts. 10 to 20% of newborns with CF present a form of intestinal obstruction called 
meconium ileus, and 2 to 5% develop liver disease at some time during the course of 
the disease. In adults with CF, infertility is almost universal in males, due to congenital 
bilateral absence of the vas deferens, and is also frequent in females. Patients also 
have elevated concentrations of sodium chloride in the sweat; in fact, the sweat test, 
which measures the amount of salt in the sweat of patients, is still one of the 
fundamental tools for the establishment of a CF diagnosis5.  
Because there are so many different disease-causing mutations in CFTR, 
mutation-specific treatments are not a viable option. Therefore, they have been 
grouped in classes based on the functional defect they confer, in order to facilitate the 
establishment of common therapeutic strategies. Class I mutations abolish protein 
production. Class II mutations result in defective protein processing; this is the case of 
the most common F508del mutation. Class III proteins confer defects in the regulation 
of the channel. Class IV mutations have a defective ion conductance. Class V 
mutations result in decreased protein synthesis. Class VI mutations decrease the 
protein’s stability in the membrane.  
Most of the different therapeutic approaches that have been used in the last 25 
years focus mainly on the amelioration of the symptoms of CF. This includes anti-
inflammatory and antibiotic drugs, as well as treatments directed towards restoring the 
levels of airway surface liquid, preventing mucus accumulation and overcoming the 
nutritional defects in patients. Currently, therapeutic focused research includes a 
multiplicity of approaches: search of candidate modifier proteins to identify new 
potential therapeutic targets and pharmacological therapy to rescue the molecular 
defects responsible for CF are the most important topics under development6. In 
January 2012, Kalydeco, the first drug targeting the molecular basis of the disease, 
was approved by the Food and Drugs Administration in the USA. This compound, 
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previously named VX-770, corrects the gating defect conferred by several mutations, 
and has been approved for patients over 6 years of age with the G551D mutation. 
Clynical phenotype of patients with the much more common F508del mutation is 
significantly improved by this drug; aditionally, ongoing clinical trials are exploring a 
combination of VX-770 with another compound, VX-809, that corrects the trafficking 
defect of proteins with other mutations, including F508del7. 
1.3 CFTR structure 
The CFTR gene (or ABCC7), is one of the longest in the human genome, 
approximately 250kb long, and encompasses 27 exons in total. It generates transcripts 
of about 6.5kb after splicing, which are translated into a protein with 1480 aminoacid 
residues.  
This protein was identified soon after its discovery as a member of the ATP-
binding cassette (ABC) transporter family due to structure similarity. Like other ABC 
transporters, it has two membrane spanning domains (MSDs) with six transmembrane 
segments each, portions of which form the pore through which anions pass, and two 
nucleotide binding domains (NBD1 and NBD2). Both NBDs bind and hydrolyse ATP, 
which drives channel opening and closure, respectively. Recent experimental data 
suggest that this is linked to dimerization of these two domains8. The most common 
mutation in cystic fibrosis patients, F508del, is located in the NBD1. In the structure of 
CFTR there is also a regulatory (R) domain that is absent in all other ABC transporters 
which contains consensus sites for phosphorylation by various kinases, including 
protein kinase A (PKA). Phosphorylation of the R domain by PKA in response to cyclic 
AMP is regarded as the major determinant for opening of the channel. In the C-
terminus, CFTR has a PSD95, Dlg1, ZO-1 (PDZ)-binding motif through which it is 
involved in complex PDZ-based protein interaction networks with a number of 
proteins9. The N-terminus is also a site for interaction with other proteins, as will be 




Figure 1.1 - Schematic representation of the structure of CFTR. Taken from Rowe (2005)
5
. 
1.4 CFTR function 
The traditional function attributed to CFTR is that of a chloride channel. Contrary to 
other ABC transporters, CFTR is incapable of actively driving ion transport against a 
gradient; instead, it functions as a passive channel that allows bidirectional flow of ions 
when open.  
The gating of the CFTR Cl− channel is tightly controlled by the balance of kinase 
and phosphatase activity in the cell and by cellular ATP levels. Activation of PKA by 
cAMP causes phosphorylation of multiple serine residues within the R domain. Once 
the R domain is phosphorylated, channel gating is regulated by a cycle of ATP 
hydrolysis at the NBDs. Finally, protein phosphatases dephosphorylate the R domain 
and return the channel to its quiescent state10.  
This PKA-mediated activation of CFTR depends on the strict compartmentalization 
of cAMP in the cell. It has been shown that the increase in cAMP necessary for PKA to 
activate CFTR must be specifically localized near the membrane, in the subcortical 
compartment11. This compartmentalization is dependent on the integrity of the 
subcortical cytoskeleton and on the presence of A-kinase anchoring proteins (AKAPs), 
such as Na+/H+ exchange regulatory co-factors (NHERFs) and ezrin, which anchor 
PKA, phosphatases, phosphodiesterases and other signaling proteins near CFTR and 
close to the membrane12.   
CFTR function is not restricted to being a chloride channel, though. It also 
permeates other anions, namely bicarbonate and glutathione.  
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It is still debated to what extent CFTR, and not the Cl-/HCO3
- transporter, which is 
also expressed in most secretory epithelia, is responsible for bicarbonate transport in 
vivo, because its permeability to this ion is low (only about 25% of that of chloride). 
However, the fact is that bicarbonate transport is impaired in CF patients, and this 
accounts at least partially for the loss of pancreatic function13,14, so even if it doesn’t 
directly permeate this anion it probably regulates channels/transporters that are 
involved in the process. 
Glutathione transport by CFTR, on the other hand, is a well established fact, and it 
has important effects on the extracellular redox balance, mucocilliary clearance, 
inflammation and immune response, processes that are impaired in the CF airways 
and pancreas. Defects in extracellular glutathione homeostasis have been proposed to 
be one of the major contributors to the exacerbation of inflammation and consequent 
deterioration of the lung tissue in CF15,16. 
Besides acting as an ion channel itself, CFTR also regulates other channels in the 
cell membrane. The mechanisms underlying this are hard to pin down, because it is not 
easy to distinguish between effects caused by changes in CFTR itself from those that 
are consequences of altered chloride conductance. Regulation of the epithelial sodium 
channel (ENaC) by CFTR is the most studied of these phenomena. ENaC is inhibited 
by increased CFTR activity, even in chloride-free media. There are three main possible 
causes for this: an increased chloride conductance might have effects per se in ENaC; 
CFTR and ENaC might be part of a macromolecular complex with proteins that 
regulate ENaC by themselves; or CFTR and ENaC might interact directly with one 
another. Compelling evidence exists to support any of these three hypotheses, so no 
consensus has been reached so far in this matter. CFTR also regulates other ion 
channels, including outwardly rectifying chloride channels (ORCCs), renal outer 
medullary potassium channel (ROMK)17, and calcium activated chloride channels 
(CaCCs)18. 
1.5 CFTR folding 
Because CFTR is such a large membrane protein, proper folding is difficult to 
achieve. In fact, at least in heterologous expression systems, depending on the cell 
type, only 20-40% of the protein escapes the endoplasmic reticulum quality control 
(ERQC) system and reaches its native conformation, with the rest being tagged for 
degradation by the ubiquitin-proteasome pathway. Whereas the NBD1 folds mostly co-
translationally, the native structure of the NBD2, and therefore of the full channel, is 
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only attained post-translationally. This slow, stepwise folding is facilitated by the 
interaction with several chaperones at the endoplasmic reticulum (ER)19. 
As CFTR begins to be translated by the ribosome, an ER targeting motif is 
recognized by the signal recognition particle, causing it to be taken to the surface of the 
ER and co-translationally inserted in the ER membrane via the translocon complex. 
While the nascent polypeptide chain is being inserted in the ER membrane, the 
exposed parts in the cytosol associate with the cytosolic molecular chaperones Hsp90, 
Hsc70/Hdj-2, and Hsp70/Hdj-1. A branched 14-unit oligosaccharide is added at 
asparagine residues 894 and  900 in the fourth extracellular loop in a process called N-
glycosylation or core-glycosylation20. Initially, this glycosidic moiety has three glucose 
residues that are trimmed away by glucosidases I and II. The chaperones calnexin and 
calreticulin recognize the monoglucosylated intermediate and shield it from the highly 
crowded environment of the ER, preventing unwanted interactions and aggregation 
with other molecules and allowing folding to progress. The protein then dissociates 
from calnexin/calreticulin and has its last glucose residue removed.  
If the protein is folded at this point, it proceeds to the secretory pathway. If, 
however, the protein didn’t attain the proper folding, it is recognized by UDP-
glycoprotein glucosyltransferase (UGGT), which re-glucosylates it and begins the next 
round of chaperone binding, deglucosylation and proofreading. If the protein undergoes 
too many of these rounds, eventually it becomes subject to ER-associated degradation 
(ERAD): it is marked by the ER degradation-enhancing α-mannosidase-like protein 
(EDEM) for degradation, is retrotranslocated to the cytoplasm and degraded by the 
ubiquitin-proteasome pathway.  
Most of the CFTR bearing the F508del mutation falls victim to the ERQC system 
and is degraded before evading the ER into the Golgi21. 
1.6 CFTR trafficking 
If CFTR folds properly and is allowed to progress to the secretory pathway, it is 
loaded into COP II-coated vesicles that bud from the ER and traffic to the Golgi. Along 
the Golgi, its glycosidic moiety is further processed into a mature, fully glycosylated, 
transport-competent form. This form has a lower electrophoretic mobility than the core-
glycosylated protein, allowing their easy distinction by Western Blotting as band C and 
band B, respectively. After this fine processing, CFTR is incorporated into secretory 
vesicles that deliver the protein into the apical membrane, where it will exert its 
functions22. Alternatively, some data suggests that at least a portion of CFTR may be 
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delivered directly from the ER to the apical membrane without going through the Golgi 
through a GRASP-dependent pathway23. 
Not surprisingly, CFTR trafficking to the membrane in epithelial cells is dependent 
on their polarization state24. Cell polarization is characterized by, among other things, a 
selective redistribution of membrane proteins among the apical and basolateral sides, 
which relies on polarized sorting and trafficking of those proteins25. However, the 
precise molecular mechanisms governing polarization-dependent delivery of CFTR to 
the apical membrane have not been well studied. 
After being delivered to the membrane, CFTR becomes subject to endocytosis. 
CFTR is internalized into early endosomes, where it can either be targeted to recycling 
vesicles containing Rab11, which will be returned to the apical membrane, or sent to 
the lysosome for degradation26.  
All these processes depend on the loading, budding, docking and fusing 
machinery that regulate intracellular trafficking that comprise a huge number of 
proteins, including Rab GTPases and soluble NSF Attachment Protein receptors 
(SNAREs). 
 
Figure 1.2 - Schematic representation of CFTR trafficking, starting at the endoplasmic reticulum. 
Adapted from Bertrand (2003)
27
. 
1.7 The CFTR interactome and Rap1A 
Throughout its lifetime, CFTR makes a very long travel in the cell, that begins with 
translation in the cytoplasm, traversing the ER and Golgi to the membrane, and being 
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recycled or sent for degradation. Along this journey, CFTR interacts with numerous 
proteins that have all sorts of effects on it. Throughout the previous sections of this 
Introduction, a reasonably large number of proteins have been mentioned as being 
relevant in CFTR biogenesis, from kinases, scaffolding proteins and chaperones to 
trafficking small GTPases and SNAREs. The number of known CFTR-interacting 
proteins (CIPs) is staggering, and it keeps on growing. Understanding how CFTR 
interacts with all these partners and how they affect it is crucial for proper therapeutic 
strategies to be devised that target the molecular basis of cystic fibrosis.  
Proteomic technologies are especially well suited to identify CIPs28,29. In 2010, 
Faria and other colleagues from our group reported having identified several CIPs with 
one such approach30. Using a recombinant CFTR NBD1 as affinity chromatography 
bait, CIPs in Calu3 (a human airway epithelial cell line) cell extracts were captured, 
separated by 2D gel electrophoresis and identified by MALDI-TOF. One of the proteins 
identified was a small GTPase called Rap1A, which will be described in the following 
sections.  
1.8 Rap1A – an overview 
Rap1A is a small GTPase belonging to the Ras superfamily of GTPases, 
specifically to the Rap subfamily. It was discovered in the late 1980s for its ability to 
revert the morphological phenotype of Ras-transformed cells. It was initially postulated 
that it merely competed for binding to Ras effectors without activating them, but this 
view has been challenged with the appearance of a myriad of Rap modulators and 
interactors with varying specificities. Rap1A is seen nowadays as a node in a complex 
signaling pathway of its own, which interacts with several other signaling pathways 
involved in key biological processes in the cell. The most prominent of these is control 
of cell adhesion, both to the extracellular matrix and to neighboring cells. It also takes 
part in regulating actin cytoskeleton dynamics and cell polarity (both in resting states 
and during cell migration), exocytosis and membrane protein recycling, and it might 
have a role in cell cycle regulation31.  
There are 5 known members of the Rap family: Rap1A and B and Rap2A, B and 
C. Rap2 proteins are mainly expressed in platelets and other hematopoietic cells, 
whereas Rap1A and B are expressed in a broader range of human tissues, including 
the lung, colon and pancreas, the most affected tissues in cystic fibrosis. Rap1A, on 









Rap1A, like all other small GTPases, cycles between two structural conformations. 
When it binds GTP, Rap1A is in an active form, capable of binding to and inducing 
specific conformational changes in downstream effectors. When it binds GDP it shifts 
to an inactive form, which is incapable of interacting with those effectors. The intrinsic 
GTPasic activity and nucleotide release rate of Rap1A are very low, so when it binds 
GTP it tends to stay locked in the active conformation, and when it binds GDP it 
remains in the inactive conformation, thus functioning as a molecular switch. 
Interconversion of these two conformations depends on auxiliary regulatory proteins 
that either activate or inactivate Rap1A. Activators are called guanine nucleotide 
exchange factors (GEFs) and act by stimulating the release of the bound GDP, 
allowing for binding of the much more abundant GTP. GTPase activating proteins 
(GAPs), on the other hand, are actually Rap inactivators, because when they increase 
the very low GTPase activity of the protein, which is where their designation comes 
from, they lead to hydrolysis of the bound GTP to GDP, converting Rap1A in the 
inactive form. Several GEFs and GAPs with varying specificities for Rap1A have been 
identified and characterized, and will be adressed in section 1.10.  
The localization of Rap1A is essential to its function, as it must be close to both its 
activators and downstream effectors in order to have an effect in the cell. Rap1A 
localization is defined by its post-translational modifications, which are discussed in 
section 1.9. While some other GTPases, from the Rho family, for instance, translocate 
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between the cytosol and the membrane (depending whether they bind proteins that 
mask the lipid anchor or not), the localization of Rap proteins doesn’t vary a lot. 
Instead, Rap signaling is spatially and temporally controlled by regulating the 
localization and activation state of RapGEFs and GAPs, respectively, as will be 
discussed in section 1.10.  
1.9 Rap1A post-translational modifications 
Rap1A is subject to four kinds of posttranslational modifications necessary for its 
proper function: prenylation and methylation of Cys181, proteolysis of the 3 C-terminal 
residues and phosphorylation of Ser180. Rap1A contains a CAAX (C – cysteine, A – 
any aliphatic aminoacid, X – any aminoacid) consensus motif in the very end of the C-
terminus that is recognized by geranylgeranyl transferase 1. The Cys residue is 
geranylgeranylated, the three last residues are proteolitically removed by a CAAX 
protease and the cysteine, now the last residue in the C-terminus, is methylated by a 
methyl transferase. The X residue at the C-terminus determines what kind of lipid 
anchor is added to the protein; for instance, Rap1A, Rap1B and Rap2A all end with 
leucine and are geranylgeranylated, whereas as Rap2B, which ends with glutamine, is 
farnesylated33. Experimental information concerning Rap2C prenylation has not been 
obtained so far. Phosphorylation of Rap1A by PKA at Ser180 appears to have an effect 
on its function, affecting its ability to bind some downstream effectors34. 
Due to its geranylgeranyl anchor, Rap1A localizes to membranes in the cell. It has 
been reported to be either perinuclear and co-localized with Golgi markers in COS-735 
cells or in a late endocytic vesicular compartment in the fibroblast cell lines BHK, 
NIH3T336 and C237. In endothelial cells, namely HUVECs38, and in epithelial cells, such 
as MCF-739 and MDCK40 cells, Rap1A is seen at the plasma membrane and enriched 
at cell-cell junction sites. Two papers reported that in CHO41, which are epithelial-like, 
and A54942 cells, which are epithelial, Rap1A has been identified in perinuclear 
locations; however, in these reports, cells were cultured in suspension, which may 
explain why Rap1A was located differently than in other epithelial cell lines. It seems to 
be a general rule that in endothelial and epithelial cells, when grown in conditions that 
allow for cell-cell adhesion to develop, Rap1A is located at cell junctions.  
Prenylation seems to be necessary for the membrane localization of Rap1A, but it 
doesn’t seem to affect which membranes it localizes to. Instead, an internal TAQST 
sequence between residues 85 and 89 seems to be responsible for its perinuclear 
location in COS-7 cells. It is unclear how it functions in maintaining Rap1A at the 
nuclear periphery in fibroblasts but not in endothelial and epithelial cells. It is likely that 
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this differential behavior involves interaction with other proteins differentially expressed 
in these distinct cell types, but this doesn’t seem to have been explored so far35.  
1.10 RapGEFs and RapGAPs 
Rap GEFs are much better understood than GAPs, and great effort has been 
focused on understanding how they activate Rap in a spatially and temporally strict 
way. Most of them respond to extracellular stimuli, relayed by either second 
messengers or tyrosine kinase receptors. Many of them also activate other Ras-family 
GTPases to lesser extents43.  
 
Figure 1.4 - Schematic representation of the multi-domain structure of RapGEFs and RapGAPs. 
Taken from Gloerich (2011)
44
. 
Epac is a 104kDa multidomain protein that activates Rap proteins in response to 
direct binding of cAMP, constituting a cAMP sensor in the cell that is independent of 
protein kinase A (PKA). Binding to cAMP has a double action on Epac: it activates it, 
allowing it to activate Rap in its turn, and it induces its translocation to the plasma 
membrane. The disheveled, Egl-10, pleckstrin domain (DEP) is necessary for this 
translocation and has been shown to tether Epac to phosphatydic acid in the 
membrane.  
Epac is also tethered to the plasma membrane by phosphorylated (active) ezrin, 
radixin and moesin (ERM) scaffolding proteins. It is worthy of note that ezrin also 
interacts with CFTR (through E3KARP/NHERF2) and with PKA, forming a 
macromolecular complex that facilitates phosphorylation of CFTR and its activation12. 
Ezrin also tethers CFTR to the actin cytoskeleton, increasing its membrane stability11. 
Radixin has also been reported to bind Epac and PKA simultaneously, bringing these 
two cAMP sensors together45. All these data suggest that Epac might co-localize with 
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CFTR, which argues for a possible function of Rap1A in regulating CFTR function or 
membrane stability. Besides, Epac is activated by stimuli that result in increased 
subcortical cAMP, the same stimuli that induce PKA-mediated activation of CFTR, 
which further supports this hypothesis. 
C3G is another GEF that has been shown to mediate signals received from B and 
T cell receptor activation, growth factors, cytokines, G protein coupled receptors and 
integrins. C3G is present in the cytoplasm in a complex with members of the Crk family 
of small adapter molecules. In response to stimuli, this complex is recruited to the cell 
membrane. This involves association of Crk with phosphotyrosine containing proteins 
like receptor tyrosine kinases, p130 Cas, insulin receptor substrate 1 and paxillin. 
Phosphorylation of C3G by Src-family kinases is also important in this translocation 
from cytosol to cell membrane. At the membrane, C3G activates downstream signaling 
by Rap1, Rap2 and R-Ras. 
Other GEFs include PDZ-GEFs, which are involved in cadherin-mediated cell-
adhesion and polarization and localize active Rap1 to the cortical cytoskeleton near the 
plasma membrane, and CalDAG-GEFs, which activate Rap1 upon binding to 
diacylglycerol, another important second messenger. 
Rap GAPs include RapGAPs I and II, the SPA-1 family (SPA-1, SPAR, SPAL, and 
E6TP1), and tuberin. These are specific to Rap proteins, but even though the catalytic 
mechanisms for Rap and Ras deactivation are different, some GAPs exist that have 
dual activity, namely GAP1IP4BP, GAP1m, CAPRI, and RASAL46. Most research on these 
regulators has focused on catalytic mechanisms and on the role of RapGAPs in 
tumorigenesis rather than in elucidating how they regulate Rap signaling. 
1.11 Rap effectors and function 
Rap signaling has been implicated in a growing number of cellular processes, of 
which the most prominent is cell adhesion, both between cells and between the cell 
and the extracellular matrix. The involvement of Rap in the establishment of cell 
polarity will also be discussed. Its role in cell migration, cell cycle regulation, 
lymphocyte-specific (reactive oxygen species formation, B- and T-cell receptor 
signaling) and neuron-specific functions (neurite outgrowth, synaptic plasticity) are 
beyond the scope of this work.  
All these functions are implicit in the set of proteins whose activity or localization 
Rap modulates. By interacting with VASP (an actin polymerizing protein)47, the 
RhoGEFs TIAM, Vav248 and FRG49 and the RhoGAPs ARAP350 and RA-RhoGAP51, 
Rap signaling causes sometimes drastic changes in cytoskeleton dynamics. Interaction 
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with Afadin/AF6 and p120-catenin is necessary for the regulation of E-cadherin stability 
at nascent adherens junctions in epithelial cells52, and interaction with CCM1/KRIT 
provides a similar role in VE-cadherin-based adherens junctions in the endothelium53. 
By activating the effectors RAPL and RIAM, Rap proteins are involved in the activation 
and clustering of various integrins and consequently in adhesion to several 
extracellular matrix proteins, including fibronectin, fibrinogen, collagen and laminin31. 
Adhesion to the extracellular matrix doesn’t seem to affect Rap signaling, though, so 
this phenomenon seems to be unilateral. Depending on the cell type and mode of 
activation, Rap1 can also activate B-Raf, a serine/threonine kinase that regulates the 
MAPK signaling pathway54. 
The regulation of cadherin stability at adherens junction by Rap signaling is one of 
the subjects of major focus in Rap-related research. Stabilization of newly-recruited E-
cadherin in nascent adherens junctions is dependent on Rap1 and is mediated by 
p120-catenin52.Although, as stated above (see section 1.9), Rap1 in epithelial cells is 
located mainly at the plasma membrane, upon the loss of adherens junctions it 
translocates to recycling vesicles that also contain endocytosed E-cadherin and Rab11. 
Furthermore, disengagement of adherens junctions results in activation of Rap1 via 
C3G, which facilitates E-cadherin recycling to the membrane and allows adherens 
junctions to be reformed40. It is interesting to note that recycling of CFTR also involves 
sorting to Rab11-positive vesicles26, making this a possible meeting point between both 
proteins. 
Rap proteins have a well described role in the establishment of cell polarity in 
neurons, where they define which out of a number of seemingly equal dendrites 
becomes the axon. In yeasts, budding is also spatially controlled in a similar fashion55. 
However, information is still scarce in what concerns the role of Rap signaling in the 
establishment of epithelial cell polarity. It has been shown that it is necessary for Arg 
kinase-dependent polarization in 3D cultures of MDCK cells56. It is also known that, in 
hepatocytes, the bile acid taurocholate increases cAMP levels in the cytoplasm, which 
are relayed to Rap1 by Epac and eventually result in the activation of the kinase LKB1, 
a master regulator of polarization in many cell types54. Although a role for LKB1 in the 
polarization of lung epithelial cells has only been shown so far in adenocarcinomas, it is 
plausible to think that this signaling module might be relevant for polarization of these 
cells in normal conditions as well. Whether this is the case or not, an effect of Rap1 in 
polarization can have an impact on CFTR biogenesis, as the delivery of CFTR to the 







The global aims of this work were to validate the previously reported interaction 
between Rap1A and CFTR and to assess the impact of up- and down-regulation of this 
small GTPase on CFTR biogenesis. In order to achieve this, several milestones were 
established, namely: 
1 – To validate the interaction between Rap1A and CFTR through co-
immunoprecipitation and immunofluorescence; 
2 – To produce plasmid constructs suitable for expression of GFP-tagged wt, 
constitutively active and dominant negative Rap1A; 
3 – To optimize transfection conditions with plasmids and siRNA and assess Rap1A 
expression and activity in transfected cells; 
4 – To evaluate the effect of up- and down-regulation of Rap1A on CFTR expression, 
trafficking and function.  
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3 Materials and Methods 
3.1 Production and characterization of vectors to study the impact of 
Rap1A on CFTR biogenesis 
3.1.1 Bacterial strain 
The bacterial strain used for cloning and DNA amplification was XL1-Blue 
(Stratagene, La Jolla, CA, USA), which is tetracycline resistant. XL1-Blue cells are 
endonuclease (endA) deficient, which greatly improves the quality of miniprep DNA, 
and are recombination (recA) deficient, improving insert stability. The hsdR mutation 
prevents the cleavage of cloned DNA by the EcoK endonuclease system. The lacIqZΔ
M15 gene on the F´ episome allows blue-white color screening. 
XL1-Blue Genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacIqZΔM15 Tn10 (Tetr)]. (Genes listed signify mutant alleles. Genes on the F´ 
episome, however, are wild-type unless indicated otherwise).  
3.1.2 Plasmid vectors and siRNAs 
 pCMV6-AC-Rap1A-GFP (RG215248, Origene, Rockvile, MD, US), which encodes 
for a Rap1A-GFP fusion protein (GFP tag at the C-terminus of Rap1A), and pCMV6-
AN-GFP (PS100048, Origene), a destination vector for expression of proteins with a 
GFP tag in the N-terminus, were used. Maps and cloning schemes for both vectors are 
available in Appendices 1 and 2. Both plasmids contain the ampicillin resistance gene, 
which was used for selection of transformed bacteria. 
The fragment containing the Rap1A open reading frame was cloned from pCMV6-
AC-Rap1A-GFP into pCMV6-AN-GFP, yielding the pCMV6-AN-GFP-Rap1A plasmid, 
as described in section 3.1.7. Variants of pCMV6-AN-GFP-Rap1A encoding for 
constitutively active (G12V) and dominant negative (S17A) mutants of Rap1A were 
obtained by site-directed mutagenesis, as described in section 3.1.8. 
siRNAs used were Silencer Select Negative control #2 (4390846), Rap1A siRNA 
(s11781) and CFTR siRNA (52945) (all from Applied Biosystems, Foster City, CA, 
USA). 
3.1.3 Production of competent bacteria 
Bacteria were plated in LB-agar medium supplemented with tetracycline and a 
single colony was used to inoculate a small volume of LB medium overnight at 37°C 
with vigorous shaking (220 rpm). This pre-inoculum was then used to inoculate at 
dilution 1/100 a larger volume of LB medium, typically 100 ml, which was also grown at 
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37°C (220 rpm) to final concentration of 5 x 107 bacteria/ml (corresponding to an 
absorbance of 0.3 at 600 nm). Bacteria were transferred to ice and pelleted by 
centrifugation (1000 g for 15 min at 4°C). The bacterial pellet was then ressuspended, 
incubated on ice for 15 min in 33mL RF1 buffer (100 mM RbCl, 50mM MnCl2, 30 mM 
KCH3COO pH 7.5, 10 mM CaCl2, 15% (w/v) glycerol, pH 5.8; all from Sigma-Aldrich, 
St. Louis, MO, USA)  and re-pelleted by centrifugation (1000 g for 15 min at 4°C). This 
second pellet was ressuspended and incubated on ice for 15 min in 8.3mL RF2 buffer 
(10 mM MOPS, 10mM RbCl,  75mM CaCl2, 15% (w/v) glycerol, pH 6.8; all from Sigma-
Aldrich). 200 μl aliquots were then rapidly frozen with liquid nitrogen and stored at -
80°C.  
3.1.4 Transformation of competent bacteria 
Bacteria were transformed by incubating a 200 μl aliquot of competent cells with 
DNA (100-200ng of ligation products; 0.1-10ng of plasmid DNA) for 30 min on ice, 
followed by heat-shock (2min at 42°C), incubation for 3min on ice, and then allowing 
antibiotic resistance to be expressed by growth in antibiotic-free LB medium for 45 min 
at 37°C at 220rpm. Bacteria were then pelleted (5000g for 2min), the supernatant was 
discarded and the pellet was ressuspended in the remaining supernatant medium. This 
suspension was then plated into LB-agar supplemented with selection antibiotic (100 
μg/ml ampicillin, Sigma-Aldrich) and left to grow overnight.  
Transformed bacterial colonies were grown in LB medium supplemented with 
100μg/mL ampicillin and used to extract plasmid DNA. Clones were stored in liquid LB 
medium supplemented with 15 % (w/v) glycerol (Sigma-Aldrich) at -20°C.  
3.1.5 DNA extraction and quantification 
Small scale plasmid DNA was purified with the PeqGOLD Plasmid Miniprep Kit 
(PeqLab, Erlangen, Germany). This protocol is based on an alkaline lysis of the 
bacterial cells in the presence of SDS, to denature bacterial proteins, followed by a 
centrifugation step to remove cellular debris, genomic DNA and denatured proteins, 
and adsorption of the plasmid DNA in the supernatant to an anionic exchange matrix in 
the presence of high saline concentrations. After adsorption, the DNA is washed and 
eluted in water or TE buffer (10mM Tris/HCl, EDTA 1mM, pH8). Sequence of plasmid 
DNA preparations was confirmed by automatic DNA sequencing at least once for every 
plasmid. 
DNA concentration was determined by measurement of absorbance at 260nm 
(one absorbance unit corresponding to 50μg/ml of dsDNA) using a Nanodrop 2000 
spectrophotometer (Thermo Scientific, Waltham, MA, USA) and its purity was 
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evaluated by assessment of the ratio A260/A280. Only DNA with a ratio above 1.8 was 
considered pure enough for further use. 
3.1.6 DNA sequencing 
Plasmid DNAs were purified as described in section 3.1.5. The sequencing 
reactions were performed using the ABI Prism BigDye Terminator Cycle Sequencing 
Kit (Applied Biosystems) according to the manufacturer’s instructions. The products 
were analyzed in the automatic sequencer 3130 XL Genetic Analyzer (Applied 
Biosystems).  Alternatively, the sequencing reactions were outsourced to StabVida, 
using BigDye Terminator 3 (Applied Biosystems) and analysed in a ABI 3730XL 
sequencer (Applied Biosystems). Sequencing primers used were VP1.5 (forward 
primer, sequence 5’-GGACTTTCCAAAATGTCG-3’) and XL39 (reverse primer, 
sequence 5’-ATTAGGACAAGGCTGGTGGG-3’) (obtained through Thermo Scientific). 
For sequence analysis, the sequences obtained were analysed through 
comparison with the reference human Rap1A sequence (NCBI reference sequence 
NM_002884.2) using the software Bioedit 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html). 
3.1.7 Cloning 
The fragment containing the Rap1A open reading frame was cloned from pCMV6-
AC-Rap1A-GFP into pCMV6-AN-GFP. Briefly, the two plasmids were separately 
hydrolysed with MluI and AsiAI (an SgfI isoschizomer) (Fermentas, Burlington, 
Canada) and the resulting fragments were separated by low-melting agarose gel 
electrophoresis. The bands containing the fragments of interest were excised from the 
gel and melted at 70ºC. The melted portions of gel containing insert and empty vector 
were combined at a ratio of 4:1, respectively, and incubated with ligase and ligase 
buffer (Roche) for 72h at 4ºC. Bacteria were then transformed with the ligation product, 
plated in LB-Agar plates supplemented with ampicillin 5ug/mL and allowed to grow 
overnight at 37ºC. Single colonies were picked to LB medium with ampicillin 5ug/mL 
and grown for plasmid extraction and sequencing. One clone containing the correct 
recombinant plasmid, pCMV6-AN-GFP-Rap1A, was chosen for further use. 
3.1.8 Mutagenesis 
Mutations were introduced into pCMV6-AN-GFP-Rap1A using the KOD Hot Start 
Kit (Novagene, Darmstadt, Germany) with complementary pairs of the custom 
designed HPLC-purified mutagenic primers described in Table 3.2 (Thermo Electron 
Corporation, Waltham, MA, USA). Primers were designed with the software PrimerX 
(http://www.bioinformatics.org/primerx). 
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The mutagenesis reaction is a regular PCR reaction, with the peculiarity being that 
the primers are not completely complementary to the template sequence; instead, they 
contain the desired point mutations. The PCR programs used are displayed in Table 
3.1. The result of this mutagenesis reaction is a mixture of the template plasmid and a 
new nicked plasmid containing the desired mutations. After confirming the amplification 
by agarose gel electrophoresis, the PCR products were incubated with DpnI 
(Invitrogen, Carlsbad, CA, USA), a restriction enzyme that specifically hydrolyzes 
methylated and hemi-methylated DNA. This results in complete degradation of the 
template DNA, which was produced in bacteria and, thus, is heavily methylated. The 
mutagenized plasmid, however, was synthesized in vitro and was not methylated, 
therefore resisting to hydrolysis by DpnI.  
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After the hydrolysis step, bacteria were transformed with the PCR products 
(section 3.1.4 from this Chapter). Bacteria not only amplify the plasmid DNA but also 
repair the nicks left by the polymerase. Following transformation, plasmid DNA was 
extracted (section 3.1.5 from this Chapter) and the presence of each mutation was 
confirmed by automatic DNA sequencing (section 3.1.6 from this Chapter). 
  
Materials and Methods 19 
 
Table 3.2 - Primers for mutagenesis reaction. The table presents only the forward primers. For 
each, a complementary reverse primer was also used.  
Name  Sequence 
G12V   5’- GGTCCTTGGTTCAGTGGGCGTTGGGAAGTC -3’ 
G15D   5’- GTTCAGGAGGCGTTGACAAGTCTGCTCTGAC -3’ 
S17A   5’- GTTCAGGAGGCGTTGGGAAGGCCGCTCTGACAGTTCAGTTTG -3’ 
DeltaT   5’- GGTGTAACTGTGCCTTTTTAGAATCTTCTGCAAAGTC -3’ 
TAAins   5’- CATGTCTGCTGCTCTAAACGCGTTAAGCGGC -3’ 
 
3.2 Biochemical and electrophysiological analysis of Rap1A impact 
on CFTR biogenesis 
3.2.1 Characterization, Culture and Maintenance of cell lines 
The majority of the experiments were performed in CFBE41o- cells57 (cystic 
fibrosis bronchial epithelial, further referred to simply as CFBE) stably overexpressing 
wt CFTR. This cell line is one of the most commonly used cell models for the study of 
CFTR in a lung context. Because they are able to polarize, these cells mimic what 
happens in the lung epithelium in physiological conditions.  
Cells were cultured in Minimal Essential Medium supplemented with L-alanyl-L-
glutamine (MEM+Glutamax) (Gibco, Paisley, UK), 10% (v/v) fetal bovine serum and 
100U/mL penicillin and 100mg/mL streptomycin (Invitrogen) in plastic flasks or plates 
coated with LHC basal medium (Invitrogen), bovine serum albumin, fraction V 
0.1mg/mL, collagen from rat tail 29μg/mL and fibronectin 10μg/mL (all from Roche). 
For polarization-dependent assays, cells were seeded in either Snapwell (Sigma-
Aldrich) or Millicell (Millipore, Billerica, MA, USA) filters at a density of 2x105 cells/filter 
coated with collagen IV (Sigma-Aldrich) and cultured with MEM+Glutamax 
supplemented with 5% fetal bovine serum (FBS) and 100U/mL penicillin and 
100mg/mL streptomycin on both apical and basolateral compartments. Transepithelial 
resistance was measured every other day with an STX2 Chopstick Electrode (World 
Precision Instruments, Inc., Sarasota, FL, USA), in order to monitor monolayer 
integrity, and experiments were performed when it exceeded 750Ω.cm2. 
Primary cultures of human bronchial cells (HBE) from 3 healthy donors were 
prepared by Marta Palma in our unit. The  access  to  explanted  lungs  was  
established  through  a  collaborative project between the Faculty of Sciences of the 
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University of Lisboa and the Cardio-Thoracic Surgery Department of the Hospital de 
Santa Marta (Lisboa), which received  approval  from  the  hospital’s Ethics  
Committee,  and  primary HBE cells were isolated as described in reference 58. 
Continuous growth was made possible by pre-confluence enzymatic dissociation 
with trypsin (Invitrogen). After dissociation, cells were resuspended and redistributed in 
new flasks or plates. Cell lines were stored in liquid nitrogen in aliquots in 40% (v/v) 
Minimal Essential Medium (Gibco), 50 % (v/v) FBS (Invitrogen) and 10 % (v/v) DMSO 
(Sigma-Aldrich), a cryoprotectant that prevents the formation of ice crystals during the 
freezing process. Freezing was performed in such a way that the cooling speed was 
about 1ºC/min, in order to minimize damage to the cells. Thawing was done by quickly 
submerging the vials in water at RT, washing the cells with F12 Medium (Invitrogen) 
and seeding in the medium described above. 
Cultures were maintained at 37ºC in a humidified atmosphere of 5% (v/v) CO2.  
3.2.2 Transfection  
CFBE cells were transfected using either cationic liposomes or electroporation. 
Lipofection is based on the ability of cationic lipids to form unilamelar liposomes 
that adsorb nucleic acid molecules to their surface and are internalized by the cells. 
The delivery mechanisms of the nucleic acid to the cytoplasm and nucleus are poorly 
understood, but the practical result is protein expression (plasmids) or down-regulation 
of the target genes (siRNAs)59. In this work, several such liposomal formulations were 
used, namely Lipofectamine 2000 (Invitrogen), Fugene HD (Promega, Fitchburg, WI, 
US) and Hiperfect (Qiagen, Venlo, Netherlands). Liposomal solutions and DNA or 
siRNA were separately incubated for 5 min in OPTIMEM (Invitrogen), mixed together 
and allowed to incubate for 15 min at room temperature (RT). They were then added 
dropwise to either 70-80% confluent cells or freshly trypsinized cells. Medium was 
changed after 24h and the experiments were performed 48-72h post-transfection. 
Another way of transfecting cells is by delivering the plasmid DNA or siRNA 
through an electrical shock. This causes transient, reversible changes in the 
organization of the lipid bilayer in the membrane, resulting in the opening of pores big 
enough for nucleic acids to enter60. A Microporator MP100 (Digital Bio, Seoul, South 
Korea) was used for electroporation experiments. Briefly, 1x105 cells were mixed with 
1.5μg of the appropriate DNA or siRNA, pipetted into a gold-covered tip and delivered a 
certain number of electrical pulses. Pulse voltage ranged from 1075-1500V, pulse 
width from 10 to 25ms and the number of pulses was 2-3. Cells were then seeded in 
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12-well plates in the medium described in section 3.2.1. Medium was changed after 
24h and the experiments were performed 48-72h post-transfection. 
For transfection with plasmids, which encode for GFP or GFP fusion proteins, 
transfection efficiency was estimated by direct counting of fluorescent vs. non 
fluorescent cells under an epifluorescence microscope (check brand). This was only 
feasible when the number of attached cells at 24h post-transfection was relatively 
small. When there was a great number of attached cells, and for siRNAs, transfection 
efficiency could only be evaluated by Western Blot. 
3.2.3 Preparation of total protein extracts 
For Western blot (WB), protein extracts were prepared by cell lysis with sample 
buffer (1.5 % (w/v) SDS; 5 % (v/v) glycerol; 0.01 % (w/v) bromophenol blue; 0.05 mM 
dithiotreitol; 0.095 M Tris pH 6.8) and DNA was sheared by passing the sample first 
through a 22G and then a 27G needle until viscosity decreased or sheared by 
enzymatic action of 5-25U/mL of benzonase (Sigma-Aldrich) in the presence of MgCl2 
2.5mM. 
Total protein concentration in different samples was assessed by a modified Lowry 
protein assay. Proteins were solubilized with 0.015% (w/v) sodium deoxycholate for 10 
min at RT, precipitated with 6% (w/v) trichloroacetic acid and then centrifuged at 14000 
g for 5 min. The supernatant was removed and the pellet was resuspended in equal 
volumes of H2O and Reagent A (0.1 g/l CuSO4.5H20; 0.2 g/l potassium tartarate; 10 g/l 
Na2CO3; 2.5% (w/v) SDS; 0.2 M NaOH) followed by 10 min incubation at RT. Finally, 
Reagent B (Folin-Ciocalteau Reagent diluted 5-fold in water) was added, followed by 
incubation for 30 min. Protein concentration was determined by measurement of A750 
and comparison with a regression line obtained for BSA (BioRad, Hercules, CA, USA) 
standards of increasing concentrations. 
3.2.4 Western blot  
After quantification of total protein (see section 3.2.3), protein extracts were 
separated by SDS-polyacrylamide gel electrophoresis (PAGE) on 7, 10 or 12.5% (w/v) 
mini-gels, followed by transfer onto Immobilon polivinylidene difluoride (PVDF) -
membranes (Millipore). After blocking with 5 % (w/v) skimmed milk in phosphate-
buffered saline (PBS, NaCl 137mM; KCl 2.7mM; KH2PO4 1.5mM; Na2HPO4 6,5mM, pH 
7.4) containing 0.1% (v/v) Tween (PBS-T) for 2 h, the membranes were probed for 2 h 
at RT with primary antibodies diluted in 5% (w/v) milk in PBS-T, washed 3x10min with 
PBS-T, followed by incubation for 1 h at RT with horseradish peroxidase-conjugated 
secondary antibodies in 5% (w/v) milk-PBS-T. Blots were developed either by 
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autoradiography or using the Chemidoc XRS+ analyser (BioRad). When 
autoradiographic detection was chosen, the signal was developed using the Immobilon 
kit (Millipore). Films were digitalized (Sharp JX-330, Amersham Biosciences, Uppsala, 
Sweden) and integrated peak areas were determined using ImageQuant TL software 
(GE Healthcare, Uppsala, Sweden). When the Chemidoc XRS+ was used, the signal 
was developed with the ImmunStar Western C Chemiluminescence kit (BioRad) and 
quantification was performed with the ImageLab software (BioRad).  
3.2.5 Rap1A activity assay 
The active fraction of Rap1A was purified using the pull-down assay described in 
reference 61. This assay is based in the specific interaction between the Rap-binding 
domain (RBD) of RalGDS and active, GTP-binding Rap1A. This domain was 
expressed fused with glutathione S-transferase, which strongly binds to glutathione-
coupled agarose beads. These beads are then used to selectively pull-down active 
Rap1A in cell extracts.  
 
Figure 3.1 - Schematic representation of the Rap1A activity assay. 
For the preparation of the beads, bacteria transformed with pGEX-RalGDS-RBD-
GST (a kind gift from Dr.David Altschuler, University of Pittsburgh School of Medicine) 
were grown in LB liquid medium until an OD600 of 0.6 was reached at which expression 
of the RalGDS-RBD-GST fusion protein was induced with IPTG 1mM (NZYTech, 
Lisbon, Portugal) for 4h. After centrifugation to collect bacteria, these were 
resuspended in PBS containing 1x Complete protease inhibitor cocktail (Roche, Basel, 
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Switzerland) and sonicated 10x 10 cycles of 0.7s. Proteins were solubilized with 1% 
(v/v) Triton X-100 (Pharmacia Biotech, GE Healthcare, Chalfont St. Giles, UK) for 30 
min at 4ºC, centrifuged at 10 000 g, 10 min and incubated with glutathione agarose 
beads (Molecular Probes, Eugene, OR, USA) for 1-2 hours at 4ºC. The beads were 
then diluted 1:1 in PBS and a 50% slurry was added 1:1 to glycerol and stored and -
80ºC.  
Induction of expression of the recombinant protein was monitored by running 
aliquots of the lysates (taken before and after addition of IPTG) in an SDS-PAGE gel, 
which was stained with Coomassie blue, showing robust expression after adding IPTG. 
Recombinant protein pull-down was monitored by running aliquots of beads taken 
before and after incubation with the bacterial lysates in an SDS-PAGE gel and staining 
with Coomassie blue, confirming that the protein was effectively captured. 
For the pull-down assays, cells were lysed on ice in Rap1A lysis buffer (25mM 
Tris-HCl, 1% (v/v) NP-40, 5mM MgCl2, 150mM NaCl, 0.1mM DTT, 5% (v/v) glycerol, 
Complete protease inhibitor cocktail, pH 7.5) for 15 min. Lysates were clarified by 
centrifugation and incubated with glutathione agarose beads coupled to GST-RalGDS 
for 1 hour at 4ºC. Beads were washed and resuspended in 1x sample buffer for 
analysis by Western Blot. 
3.2.6 Immunoprecipitation 
CFBE cells overexpressing wt CFTR were grown in P100 plates until confluency 
was reached, lysed with 1mL PD buffer  (50mM Tris-HCl, 0.1M NaCl, 1% (v/v) NP40 
(Roche), 10% (v/v) glycerol, supplemented with a 1x Complete protease inhibitor 
cocktail, pH 7.5) at 4ºC and collected with a cell scraper. Cell membranes and debris 
were pelleted by centrifugation at 10000rpm for 5min at 4ºC and the supernatant was 
incubated at 4 ºC overnight with the appropriate antibody and 40uL of Protein-G 
agarose beads (25μg) (Invitrogen). The beads were pelleted by centrifugation for 1min 
at 13000rpms, washed 3x with wash buffer (Tris-HCl 0.1M pH 7.5, NaCl 0.3M, Triton X-
100 1% (v/v)) and eluted with 1x sample buffer. The immunoprecipitate was 
electrophoretically separated on SDS-PAGE gels and analysed by Western Blots (see 
section 3.2.4).   
3.2.7 Immunofluorescence 
Cells were grown in filters to achieve polarization (see section 3.2.1) until a 
minimum resistance of 800Ω/cm2 was reached.  Cells were washed 3x with PBS, fixed 
for 30min-1h with 4% (v/v) formaldehyde, washed 3x with PBS, permeabilized for 10-
15min with Triton X-100 0.5% (v/v) and washed again 3x with PBS. A blocking step 
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with PBS with 1% (w/v) BSA (30min) was performed to avoid unspecific binding of the 
antibodies. The filter with cells was cut into several pieces with an adequate size for 
imaging and each piece was incubated in a humid chamber with a specific primary 
antibody diluted in PBS with BSA 1% (w/v) for 1h. The filter pieces were washed 3x 
with PBS with Triton X-100 0.05% (v/v) and incubated in a humid chamber with 
secondary antibody diluted in PBS with BSA 1% (w/v) for 1h. Filters were then washed 
3x with PBS with Triton X-100 0.05% (v/v), post-fixed with 4% (v/v) formaldehyde for 
10min and washed again 3x with PBS with Triton X-100 0.05% (v/v). The filter pieces 
were mounted in glass slides with Vectashield mounting medium (Vector Laboratories, 
Burlingame, CA, USA) containing DAPI (Sigma-Aldrich) and sealed. 
Immunofluorescence staining was observed in a Zeiss Axiovert 200M microscope 
(Zeiss, Jena, Germany) orin a Leica DMI4000B confocal microscope (Leica 
Microsystems, Wetzlar, Germany). 
3.2.8 Antibodies 
Antibodies used are summarized in Table 3.3. 
Table 3.3 - List of primary and secondary antibodies used. 













CFTR (NBD2) 596 (Cystic Fibrosis Foundation) WB (1:3000), IP (1:1000) 
CFTR (R domain) 570 (Cystic Fibrosis Foundation) 
IF (1:250 for wt, 1:200 for F508del 
CFTR) 
Rap1A 
sc-1482 (Santa Cruz 
Biotechnology, Santa Cruz, CA, US) 
WB (1:200), IF (1:50), IP (1:100) 
α-tubulin T5168 (Sigma WB (1:20000-1:30000) 
Epac/RapGEF3 
ARP52140_P050 (Aviva Systems 
Biology, San Diego, CA, US) 
WB (1:1000) 
E-cadherin 
610181 (BD Biosciences, San Jose, 
CA, US) 
IF (1:200) 













s Mouse IgG, HRP-conjugated NA931V (Amersham) WB (1:3000) 
Rabbit IgG, HRP-conjugated NA934VS (Amersham) WB (1:5000) 
Mouse IgG, Alexa 568-conjugated A10037 (Invitrogen) IF (1:500) 
Rabbit IgG, Alexa 488-conjugated A21206 (Invitrogen) IF (1:500) 
 
3.2.9 Ussing Chamber assays 
Briefly, the basolateral surface of the CFBE monolayers grown in Snapwell 
(Sigma-Aldrich) filters was continuously perfused (5 ml/min) with Ringer solution of the 
following composition: NaCl 145mM, KH2PO4 0.4mM, K2HPO4 1.6mM, D-glucose 5mM, 
MgCl2 1mM, calcium gluconate 1.3mM. The apical bath solution was perfused with a 
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low Cl- Ringer solution containing: NaCl 32mM; KH2PO4 0.4mM; K2HPO4 1.6mM; D-
glucose 5mM; MgCl2 1mM; calcium gluconate 5.7mM and sodium gluconate 112mM. 
The pH of all bath solutions was adjusted to 7.4 and all experiments were carried out at 
37 °C under open circuit conditions. Cell monolayers were equilibrated in the micro-
Ussing chambers for at least 20min in perfused Ringer solution before the experimental 
protocol and then perfused sequentially with the cAMP-elevating agent forskolin at 
2μM, forskolin 2μM and the CFTR potentiatior genistein at 25μM, and finally with the 
specific CFTR inhibitor CFTR Inh172 30μM. 
Values for the transepithelial voltage (Vte) were recorded continuously and were 
referred to the basolateral surface of the epithelium. Transepithelial resistance (Rte) 
was determined by applying intermittent (1s) current pulses (0.5µA). The equivalent 






4.1 Rap1A expression in CFBE cells and primary cultures of human 
bronchial cells 
The central question of this work, whether or not Rap1A has an impact on CFTR 
biogenesis, is only relevant if Rap1A is expressed in the same cells where CFTR has 
an important function. Since the most clinically relevant defect in cystic fibrosis is 
caused by CFTR malfunction in the lung epithelium, it was of special interest to see if 
Rap1A was expressed in lung epithelial cells. To answer this question, Rap1A 
expression was assessed by Western blotting in the CFBE wt cell line and in primary 
cultures of human bronchial epithelial cells from three healthy donors, using a specific 
Rap1A antibody. Since the RapGEF Epac is activated by cAMP (the same second 
messenger that signals for CFTR activation) its expression was also evaluated.  
 
Figure 4.1 - Western blot of protein extracts from CFBE and HBE cells using A) anti-Rap1A 
antibody and B) anti-Epac1 antibody. HBE cells were always grown in filters and polarized. The 
HBE blots are representative of experiments with cells from 3 different non-CF donors.  
Rap1A expression was confirmed with the appearance of a ~20kDa band in HBE 
and CFBE cells (both polarized in filters and grown in plastic, with no differences). 
Later on, this ~20kDa band was seen to disappear in CFBE cells transfected with 
Rap1A siRNA, confirming its identity (see Figure 4.8).  
Regarding Epac expression, it is harder to be sure how to interpret the band 
pattern obtained. The Epac family comprises 3 members: Epac1 (104kDa), Epac2 
(115kDa) and Repac (63kDa). Although it was raised against Epac1, the antibody 
might be able to detect the other highly homologous Epacs, especially being a 
polyclonal antibody. Also, Epac1 might be subject to alternative splicing, yielding two 
different isoforms of 104 and 66kDa (UniprotKB accession numbers O95398 and 
O95398-2, respectively), further complicating the interpretation of the Western blot. 
This would need further experiments to clarify: RT-PCR with isoform specific primers to 
analyse mRNA expression, knockdown with isoform-specific siRNAs to compare the 




Regardless of this, the bands that were present in the Western blots were clear and 
had high intensities, suggesting that they are specific, thus indicating that some 
isoforms of Epac are expressed in these cells. Interestingly, the band pattern for the 
Epac antibody changed when CFBE cells were polarized, something that hasn’t been 
reported in the literature so far. 
With the expression of Rap1A confirmed, its localization was assessed by 
immunofluorescence in polarized CFBE wt cells, in parallel with staining for CFTR and 
E-cadherin.  
Staining of endogenous Rap1A gave signals of very low intensity, even though the 
antibody was at a high concentration. The protein seems to have a dispersed 
localization in the cell, either in the cytoplasm or the plasma membrane. However, it 
appears to be enriched in cell-cell junctions, where it co-localizes with E-cadherin. This 
is expected, as Rap1A is reported to be located in adherens junctions in other epithelial 
cell types, namely in the Marbin-Darby canine kidney (MDCK) cell line64. The 
distribution of Rap1A and CFTR also seem to overlap, which supports a possible 
interaction, but this is difficult to ascertain due to the weak staining for endogenous 
Rap1A. 




4.2 Co-immunoprecipitation  
 To evaluate the proposed interaction between Rap1A and CFTR, co-
immunoprecipitation experiments were performed.  
Overexpressed CFTR and endogenous Rap1A were immunoprecipitated in 
parallel, and cross-detection in the immunoprecipitates was performed by Western 
Blotting. A negative control was included in which the whole protocol was done without 
the addition of antibodies, to discard any non-specific binding to the Protein-G-coupled 
agarose beads.  
Results however were inconclusive, hardly indicating the presence of Rap1A in the 
same protein complexes as CFTR.  
4.3 Molecular cloning and mutagenesis 
The next task consisted in producing plasmid vectors for expression of Rap1A, as 
well as three mutants previously reported in the literature. These mutants were:  
- G12V, which is reported to display constitutive activation65;  
- G15D, which is insensitive to Epac but is still capable of being activated by 
C3G; 
- S17A, which has been described as the most effective dominant negative in the 
literature66.  
The starting materials, which were already available in the lab prior to the start of 
the work, were pCMV6-AC-Rap1A-GFP, a plasmid which encodes for a wt Rap1A 
fused with an GFP-tag in its C-terminus, and pCMV6-AN-GFP, an empty vector 
designed for expression of N-terminally GFP-tagged proteins. pCMV6-AC-Rap1A-GFP 
has an SgfI restriction site at the beginning of the Rap1A ORF and an MluI site at the 
end, which are compatible with sites for the same enzymes in the pCMV6-AN-GFP 
vector. Both vectors also encode for ampicillin and neomycin resistance genes for 
selection in bacteria and mammalian cells, respectively. Plasmid maps are included in 
the Appendices (section 0). 
First of all, the original plasmids were sequenced. Analysis of the sequences 
revealed an insertion of one thymine in the middle of the Rap1A ORF, which caused 
the downstream portion of the ORF to be out of frame. A preliminary mutagenesis 
reaction was performed to eliminate this problem using the DeltaT primers and 




Figure 4.3 - Sequence of the original pCMV6-AC-Rap1A-GFP plasmid showing A) an insertion of a T 
and B) removal of this T after the mutagenesis. 
To circumvent possible folding and stability issues caused by the introduction of 
the GFP-tag on the C-terminus of the protein, it was found useful to also have a vector 
for expression of an N-tagged construct. Upon further research into the literature, this 
was considered an absolute necessity, due to the fact that Rap1A is subject to 
geranylgeranylation, proteolysis and methylation in the conserved CAAX motif in its C-
terminus. A C-terminal GFP tag is likely to mask this recognition site, disrupting the 
protein’s processing, localization and function, as was later seen to be the case. 
Therefore, the Rap1A cDNA in pCMV6-AC-Rap1A-GFP was cloned into pCMV6-AN-
GFP. 
The cloning procedure was performed as described in the section 3.1.2 of the 
Materials and Methods. Ligation products were used to transform bacteria, after which 
several transformed colonies were picked and grown separately in liquid medium. 
Plasmids were then purified and four clones were analyzed by agarose gel 





Figure 4.4 - Agarose gel electrophoresis of the products of ligation of the Rap1A cDNA from 
pCMV6-AC-Rap1A-GFP into the pCMV6-AN-GFP vector. 
 Plasmids extracted from all four clones showed a decrease in their electrophoretic 
mobilities, suggesting an increase in mass that was compatible with the insertion of the 
555bp Rap1A cDNA.  
These plasmids were then sequenced (Section 3.1.6) to confirm successful 
ligation, as shown in Figure 4.5. A single clone (clone 6) was selected for further use. 
 
Figure 4.5 - Sequencing results for the ligation product pCMV6-AN-GFP-Rap1A (clone 6), showing 
correct insertion of the Rap1A cDNA directly downstream of the GFP cDNA and in frame. 
After finishing the cloning, an additional mutagenesis reaction had to be 
performed. The Rap1A ORF from the original plasmid didn’t have an endogenous 
STOP codon, as it was tagged with the GFP in the C-terminus, and the destination 
plasmid is built in such a way that it appends two codons to the end of the ORF before 
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the STOP codon in order to generate a suitable MluI restriction site in its C-terminus. 
Having two additional aminoacid residues in the C-terminus of the protein would likely 
prevent recognition of the prenylation site mentioned before, altering the protein’s 
localization and function. Therefore, this mutagenesis was performed using the primers 
TAAins (see section 3.1.8), which were designed to insert a STOP codon (TAA) 
between the desired last codon of the ORF and the two unwanted, additional codons. 
The mutagenesis products were sequenced and the insertion of the STOP codon 
confirmed shown in Figure 4.6, with the plasmid being considered suitable for further 
use. 
 
Figure 4.6 - Sequencing results confirming correct insertion of a STOP codon at the end of the 
Rap1A ORF. The two additional codons are highlighted in red. 
Finally, the constitutively active and dominant negative mutants were produced, 
using the G12V, G15D and S17A primers and the programs described in section 3.1.8. 
Even after trying to optimize the PCR conditions, the mutagenesis for the G15D mutant 
was unsuccessful. All clones picked showed insertion of one or more sets of primers 
into the target region of the plasmid, possibly due to self complementarity of the 
primers. The production of this mutant was therefore abandoned due to time 
constraints. The products of the other two mutagenesis reactions were used to 
transform bacteria, purified and sequenced, as shown in Figure 4.7, confirming 




Figure 4.7 - Sequencing results confirming correct production of the constitutively active (G12V) 
and dominant negative (S17A) mutants. 
4.4 Transfection optimization 
Two transfection methods were used in the course of this work, electroporation 
and lipofection. The latter was performed with three different reagents, Lipofectamine 
2000, Fugene HD and Hiperfect. 
The CFBE cell line is an immortalized epithelial line that is not particularly easy to 
transfect, as occurs for epithelial cells in general. Initially, transfection with the empty 
pCMV6-AN-GFP vector, which only encodes for GFP, using Lipofectamine 2000 
yielded very few transfected cells and low cell viability. High transfection efficiency is 
necessary to see any possible effect of Rap1A on CFTR biogenesis, particularly if this 
effect is of small magnitude; otherwise, changes in a few transfected cells won’t be 
seen in experiments made with the whole cell population. Good cell viability is also 
important, particularly for CFTR function analysis in Ussing chambers, where a tight, 
polarized and completely confluent monolayer of cells is required. Thus, it became 
necessary to optimize the transfection procedure. The outcome of this optimization is 
summarized in Table 4.1. 
Table 4.1 – Transfection efficiency and cell survival rate of the best conditions for each method 
used. 
  DNA siRNA 




Electroporation 30-40% 10-20% 80-90% 75% 
Lipofectamine 2000 10-20% 30-40% 20% 90-100% 
Fugene HD 30-40% 90% - - 




For plasmid transfection, Lipofectamine 2000, Fugene HD and electroporation 
were used. In the beginning of the optimization process, transfection efficiency and cell 
viability were only monitored visually, as the plasmids encode for GFP or GFP 
constructs. When the need for more objective criteria was acknowledged, transfection 
efficiencies were estimated by directly counting green and total cells in the 
epifluorescence microscope in at least three different visual fields. This was only 
possible when cell viability was low and become unfeasible when many cells survived. 
A more accurate alternative would have been to trypsinize the cells before the 
experiment and count them in a haemocytometer. 
Several experiments were made with Lipofectamine with varying Lipofectamine 
volumes and DNA amounts, but even the best conditions yielded very low transfection 
efficiency, about 10%, and very few cells survived. Electroporation yielded higher 
efficiencies of about 30-40%, depending on the plasmid, but few cells survived as well. 
Fugene HD was the selected method of choice for plasmids, as it yielded about 30-
40% efficiencies and had a very high survival rate, with cells practically reaching 
confluence 48h later. For an illustrative Western Blot with extracts of cells transfected 
with FuGene, see Figure 4.9. This efficiency is still not as high as would be desirable, 
but it was as much as could be obtained. 
It should be noted that transfection efficiency and fluorescence intensity in 
transfected cells were highly dependent on the plasmid. The plasmid encoding for the 
constitutively active mutant yielded the highest number of transfected cells and cells 
were brightly fluorescent. The dominant negative variant was the opposite, giving few 
and dimly fluorescent transfected cells, and the wt plasmid was in between. This was 
consistent between experiments and reagents. 
For siRNA transfection, Lipofectamine 2000, Hiperfect and electroporation were 
used. Evaluating knockdown was only possible through Western Blot analysis. A 
validated siRNA against CFTR was used as a positive control and a scrambled siRNA 
was used as a negative control in order to discard non-specific effects. Lipofectamine 
was ineffective, having caused comparable decreases in CFTR levels with the 
scrambled and the CFTR-specific siRNA. Transfection of the CFTR siRNA with 
Hiperfect resulted in more pronounced decreases, having diminished CFTR levels to 
approximately 45% of the levels in non-transfected cells and Rap1A to approximately 
20%, with viabilities between 80-90%. Electroporation, albeit being more aggressive to 
the cells and killing about 25% of them, was the most effective method by far, causing 
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a decrease in protein levels of up to 80-90%, and was thus considered the method of 
choice for siRNA transfection. These results (n=1) are illustrated in Figure 4.8. 
 
 
Figure 4.8- Comparison of knockdown efficiency with different transfection methods. Protein levels 
are expressed as percentage of the targeted protein in non-transfected samples; CFTR levels 
correspond to total CFTR (Band B + Band C). Rap1A levels after transfection with Lipofectamine 
were not available, due to problems with detection in the Western Blot. N=1. 
In all of these transfection experiments, cells were seeded in uncoated plates. At a 
certain point, the question arose of whether the lack of coating was making it harder for 
the cells to adhere to the plates, as this might contribute to the high death rates that 
were being obtained so far. An experiment was made in which the cells were 
transfected with pCMV6-AN-GFP, pCMV6-AN-GFP-Rap1A or without DNA and seeded 
in parallel into coated and uncoated plates, but no difference in either cell survival or 




































already seeded and about 60-80% confluent at the time of transfection was also 
performed, but resulted in a much lower efficiency. 
4.5 Rap1A expression and activity and its impact on steady-state 
CFTR 
When suitable transfection conditions were defined, CFBE cells were transfected 
with the several plasmids available. The expression of Rap1A and CFTR was 
evaluated by Western Blotting. In parallel, a pull-down based Rap1A activity assay 
(described in section 3.2.5) was also performed, with two objectives: to confirm that the 
constitutively active and dominant negative mutants were behaving as expected and to 
see if the increase in total Rap1A protein was accompanied by an increase in active 
Rap1A. This last topic is important because signaling by small GTPases is regulated 
mainly by changes in their activation state, rather than by modulating the amount of the 
GTPase, as can be inferred by the large amount of different GEFs and GAPs existent. 
Results are shown in Figure 4.9.  
 
Figure 4.9 – Rap1A expression and activity and its effect in steady-state CFTR. Western Blots of 
Rap1A in (A) whole cell extracts and (B) active Rap1A precipitates of cells transfected with the 




The C-tagged wt construct is not expressed with the expected molecular weight of 
~47kDa. This is not surprising, as the CAAX motif, which is responsible for correct post-
translational modification of the protein to its mature, membrane-bound form, is in the 
middle of the protein and not in the C-terminus as in the wt protein.  Therefore, this 
construct is probably misprocessed; this would correspond to the band with smaller 
electrophoretic mobility that is present in the respective lane in the blot. This is 
compatible with the fact that there is no band in the active Rap1A blot for this construct. 
 Surprisingly, though, the N-tagged wt and constitutively active variants also show 
this band, and it is actually more intense than the one with the expected molecular 
mass. This probably means that, maybe due to the bulky GFP-tag, these constructs 
are not being correctly processed. The GFP tag might somehow sterically hinder the 
access of processing enzymes to the CAAX motif. Another possibility is that due to the 
GFP tag a fraction of the protein is locked in a conformation where that motif is 
masked, preventing the correct processing of the protein and its membrane targeting. 
Whatever the reason may be, this fraction of the protein does not show up in the active 
Rap1A blot, and is therefore not active. The correctly processed fractions of both 
constructs are active. The amount of active Rap1A seems to be proportional to the total 
amount of Rap1A, suggesting that the wt protein already displays high activation levels. 
These activation levels are probably intrinsic to the protein and not due to tonic 
activation by GEFs, because the endogenous protein barely showed up in the blots, so 
it should be mostly inactive. 
Curiously, the dominant negative mutant doesn’t show the lower molecular mass 
band. Furthermore, it gave an intense band in the active Rap1A blot, which can mean 
one of two things: either it is effectively active, or it is not active but still has affinity for 
the bait used in the Rap1A activity assay, in contradiction with the literature66.  
Taken together, these results motivated the exclusion of both G12V and S17A 
mutants from this study. Because the wt construct already shows high activation levels, 
the G12V mutant became obsolete. The S17A mutant, on the other hand, did not 
behave as a dominant negative at all, so it was discarded as well. The experiments 
continued with the wt construct only; despite of a good portion of it being assumedly 
misprocessed, a significant fraction still showed up at the expected molecular mass in 
the Western blots. The fact that it showed such intense bands in the active Rap1A blot 
is not ideal, but it should still allow for further work.  
No significant alterations to the amount of steady-state CFTR were observed with 
any of the constructs. This might be because Rap1A has no effect on CFTR biogenesis 
at all in the conditions of these experiments or because the effect is too small to be 
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observed, due to the rather low transfection efficiency (30-40%) or to the small amount 
of functional exogenous Rap1A in transfected cells. These results might have been 
different if the cells were grown in filters and allowed to polarize; however, transfection 
of polarized CFBE cells is even more difficult to achieve, as can be seen later in 
section 4.6, especially with plasmid DNA. 
4.6 Ussing chamber analysis of CFTR function upon down-regulation 
of Rap1A  
CFBE cells overexpressing wt CFTR were transiently transfected in suspension 
with scrambled siRNA or Rap1A siRNA using Lipofectamine 2000 and seeded in 
coated Snapwell filters. Transepithelial resistance was measured 96h post-transfection 
and found to be between 750 and 1960 Ω.cm2, which indicates that the cell monolayer 
was electrically tight and polarized enough for Ussing chamber analysis.  
The Ussing chamber protocol was then performed. Briefly, the cells were perfused 
in the luminal side with: 
1) Ringer solution 
2) Forskolin 2μM; forskolin is an adenylate cyclase agonist which rapidly increases 
cAMP levels in the cells; for this reason, it is used as a CFTR activator63. 
3) Forskolin 2μM + genistein 25μM; genistein is a CFTR potentiator and increases 
forskolin-induced chloride currents both in wt and F508del CFTR67. 
4) CFTR Inh172 30μM, a commonly used specific inhibitor of CFTR currents.68 
Shown in Figure 4.10 are representative tracings of each experience. 
 
 
Figure 4.10 - Ussing chamber measurement of CFTR funtion upon downregulation of Rap1A. 
Tracings are original recordings representative of 3 and 4 experiments with cells treated with 
siScrambled and siRap1A, respectively. 
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The results of the Ussing chamber experiments were then quantified and 
summarized in Figure 4.11. 
 
Figure 4.11 - Effect of Rap1A down-regulation in CFTR function. CFBE cells were transiently 
transfected with siScrambled (n=4) or siRap1A (n=3) and polarized in Snapwell filters. 96h post-
transfections, cell monolayers were perfused in Ussing chambers with Ringer solution (control), 
forskolin 2 M, forskolin 2 M + genistein 25 M and CFTR inh172 30 M. Transepithelial voltage and 
transepithelial resistance were measured and converted into equivalent short-circuit current 
measurements. Values are means + SEM. 
No statistically significant differences were measured between the currents elicited 
in siRap1A-transfected cells relative to siScrambled-transfected cells. After completion 
of the experiments, cells were lysed in 1x sample buffer and subjected to Western Blot 
























Figure 4.12 - Western Blot analysis of CFTR, tubulin and Rap1A expression in the cells used for the 
Ussing chamber experiment.  
Because the lanes had different amounts of total protein, as assessed by the 
different intensities of the tubulin bands, band intensities needed to be quantified to 
allow for correct interpretation of the Western Blot. After normalizing CFTR and Rap1A 
band intensities to tubulin band intensities, there was no significant difference between 
Rap1A expression in cells transfected with siRap1A and siScrambled (p=0,40). This 
indicates that the transfection was not efficient; the consequence of this is that it is 
difficult to draw conclusive outcomes from the Ussing chamber functional assessment. 
If Rap1A down-regulation has some impact on CFTR expression and trafficking (as 
seen by Western Blot), as well as in its function (as seen by Ussing chamber analysis), 
this can only be seen if Rap1A is efficiently down-regulated, otherwise the effect is very 
small and becomes masked by the experimental noise.  
The expression of Rap1A and CFTR was then analysed in each sample. Treating 
the data this way has the advantage that all the samples are treated equally instead of 
being grouped into two distinct classes which were not significantly different from one 
another in this experiment. Besides, Rap1A values in each class were not very 
homogeneous, probably due to differences in transfection efficiency and/or survival and 
growth rates in each sample; this too is disadvantageous when dealing with a class-
based analysis. 
The Band C/Band B ratios, indicative of the proportion of CFTR that has been 
correctly processed, and the forskolin-induced and genistein-induced Isc values did not 
correlate well with Rap1A levels. However, there seems to be a tendency for higher 
 51 
 
total CFTR expression and higher band C intensities in samples in which Rap1A is 
more expressed, as evidenced in Figure 4.13.  
  
Figure 4.13 – Relationship between Rap1A and CFTR expression. Total CFTR levels refer to the 
cumulative intensities of band C and band B. Both CFTR and Rap1A band intensities were 
normalized to the respective tubulin band intensities. Linear regression was done using the least 
squares method. 
5 Discussion 
5.1 Validation of the central questions 
As described in section 1.7, the two central questions this thesis tries to answer 
were prompted by results from former colleagues who performed a screen for potential 
CFTR-interacting proteins using an affinity purification protocol where proteins that 
interacted with the NBD1 of CFTR in Calu-3 cell extracts were captured. This was 
followed by separation of the captured proteins by 2D gel electrophoresis and their 
identification by mass spectrometry. One of the hits in this screen was identified as 
being the small GTPase Rap1A. However, further analysis of the mass spectrometry 
data revealed that this was probably a misidentification. 
First of all, there was a discrepancy between the molecular weight of the spot in 
the gel (85kDa) and the associated hit obtained by analysis of the MS data with the 
Mascot software (21kDa). Furthermore, the hit was described in early, non-published 
reports as Raichu404X (Genbank ID BAB61868), not Rap1A. Raichu404X is an 
artificial construct that functions as an auto-FRET probe, and it is used to view Rap1A 
activation in the cell using fluorescence microscopy. It is thus not to be expected that 
such an artificial construct would be expressed in the Calu-3 cell line. Also, only one 
peptide fragment was used for this identification in the mass spectrometry study.  
R² = 0,81 
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In light of this, there is no reason to believe Raichu404X was indeed the protein 
identified in the screen. A much more appealing candidate would have been 
phospholipase C β3, a more expectable hit that came with a lower score.  
The possibility of the existence of a complex containing Rap1A and CFTR still 
exists, although to my knowledge there is no data in the literature that directly support 
this hypothesis. However, even if there is no physical interaction between Rap1A and 
CFTR, this GTPase may have an effect, albeit indirect, on CFTR biogenesis. Rap1 
signaling has a known role in exocitosis in specialized cells, namely sperm69, neurons 
and insulin secreting beta-cells70,71. Also, Rap1A is involved in E-cadherin recycling via 
vesicles containing Rab11 vesicles, and CFTR recycling also requires Rab11-positive 
vesicles. Since recycling of CFTR has an important role in the amount of protein at the 
plasma membrane26, this is a process in which Rap1A could affect its steady-state 
membrane levels. Rap1A has also been shown to be necessary for proper polarization 
of neurons72,73, yeasts55, endothelial cells53 and lymphocytes74 and it seems to have 
some role in the establishment of polarity in epithelial cells56,75. This makes it likely that 
it will exert some kind of influence on CFTR, since trafficking of CFTR to the membrane 
is dependent on cell differentiation and polarization76. In addition to this, Rap1A is a 
known regulator of the Rho signaling pathway48, which controls cytoskeletal dynamics 
and, specifically, CFTR stability in the plasma membrane via ezrin (Paulo Matos, 
personal communication). Finally, the RapGEF Epac can be located at the membrane 
by ezrin, and Epac-Radixin-PKA complexes45, as well as ezrin-PKA-CFTR complexes12 
have been reported in the literature. This makes it possible that a Rap activator and 
Rap itself are very close to CFTR. Coincidentally, this GEF activates Rap in response 
to the same stimuli that activate CFTR.  
All this data supports the hypothesis that Rap signaling has a potential effect on 
CFTR trafficking and function. Since Rap1A is expressed in primary cultures of human 
bronchial epitelial cells, as well as in the epitelial cell line used, as was seen by 
Western Blot in this work, it seems valid to question whether Rap1A affects CFTR 
biogenesis, trafficking and function. 
5.2 Objective 1 – Producing plasmid constructs 
The first objective consisted in producing plasmid constructs for expression of 
GFP-tagged wt, constitutively active and dominant negative Rap1A. These constructs 
were produced and they allowed for expression of these Rap1A variants; however, 
these constructs seem to express variants of the protein with disrupted folding and/or 
processing of the protein, which can be seen by the appearance of a band of higher 
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electrophoretic mobility in the Western Blots. This band was expected to appear in the 
C-tagged construct, due to masking of the –CAAX motif, but not in the other constructs. 
The presence of some misfolded or misprocessed recombinant protein wouldn’t 
normally be too much of a problem, except that it was considerably more abundant 
than the correctly folded/processed protein for the wt and constitutively active 
constructs. Besides, accumulation of misfolded or misprocessed protein can trigger an 
unfolded protein response (UPS) in the cell77, likely affecting CFTR biogenesis and 
confusing the results. The most plausible for this problem is the size of the GFP tag, 
which increases by approximately two-fold the size of the expressed protein when 
compared to Rap1A alone. 
5.3 Objective 2 – Optimizing transfection and assessing Rap1A 
expression and activity 
One of the major problems in this work was the fact that CFBE cells are hard to 
transfect, as it happens for epithelial cells in general78. Even with several attempts at 
optimizing the procedures and using several liposomal reagents, transfection of 
plasmid DNA yielded 30-40% efficiencies at best, which were not enough to detect an 
effect with statistical significance.  
The results of the Rap1A activity assays were unexpected. The fact that the 
dominant negative S17A mutant gave intense bands in the activity assay is in direct 
contradiction with the literature66. It is possible that the GFP tag stabilizes the GTP 
bound conformation of Rap1A S17A, or that it facilitates an interaction between Rap1A 
and the RalGDS-RBD (the bait used in the assay) or even that GFP itself is capable of 
binding RalGDS-RBD.  
It is important to note that the assay used is not exactly an activity assay in the 
common sense of the term, but rather a binding assay. Because Rap1A function is 
directly related to its ability of binding effectors and inducing conformational alterations 
in them, its affinity for the effectors is generally assumed to be a measure of its 
biological activity. Whether the S17A protein pulled-down was in fact active or was 
caused be artifactual binding of the protein to the bait remains to be seen. A way to test 
this hypothesis would be to measure an actual output of Rap1A activation, like B-Raf 
activation, in the cells transfected with the S17A construct versus cells transfected with 
non-tagged wt Rap1A. 
The fact that the wt and constitutively active constructs yielded bands of relatively 
similar intensity might be due to tonic activation of Rap1A in these cells in the culture 
conditions used; however, active endogenous Rap1A levels seemed low compared to 
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exogenous active Rap1A levels, which makes this hypothesis unlikely. A more 
plausible explanation is that the G12V mutant is not entirely unsensitive to RapGAPs, 
even though it is established in the literature as a bona fide constitutively active mutant. 
In fact, Brinkmann and colleagues have shown that the G12V mutant is inactivated by 
RapGAP179. An alternative mutant might be F64A, which is not inactivated by this 
GAP. 
5.4 Objective 3 – Validating the CFTR-Rap1A interaction 
Accounting for the increasing number of cellular processes, especially those 
related to cell differentiation and protein trafficking in which CFTR seems to play an 
active role, an interaction between CFTR and Rap1A is possible, especially if taking 
into account that interactions between Epac, ezrin/radixin, PKA and CFTR have been 
reported. The main strategy for validating this interaction was, as is usual in this kind of 
studies, immunoprecipitation. However, detecting Rap1A was very difficult. 
Optimization of Western blot for Rap1A achieved during the final stages of this work 
will allow these experiments to be performed, and thus to evaluate properly the 
interaction between CFTR and endogenous Rap1A. Testing this with overexpressed 
Rap1A should only be done when more appropriate constructs are generated, because 
not only is the bulky GFP tag likely to disrupt the folding and/or processing of Rap1A, it 
might also interfere with such an interaction. 
5.5 Objective 4 – Effect of up and down-regulation of Rap1A on CFTR 
The Ussing chamber experiments did not reveal any significant differences in 
CFTR function upon downregulation of Rap1A. This probably arises from the modest 
transfection efficiencies obtained, not necessarily from a lack of effect. It is also 
important to notice that there is the possibility that other Rap family members might 
compensate for the loss of Rap1A, since at least some of their functions are redundant. 
In fact, in many papers Rap1A and Rap1B are treated as a single entity, even though 
in fact they are two different proteins (which is somewhat misleading, though, because 
despite their 95% homology, their functions are not completely overlapping38). Besides, 
most research so far has focused on Rap1, leaving Rap2 proteins relatively obscure; 
they may also at least partially compensate for the loss of Rap1A. 
 It is usual in this kind of experiments to do a comparison with non-treated cell 
monolayers as a negative control. This would have allowed to see if the lack of 
difference in Rap levels between scrambled and Rap siRNA were due to the scrambled 
siRNA down-regulating Rap as an off-target effect. However, this didn’t happen in other 
transfections, so it’s an unlikely possibility. Besides, due to time constraints, 
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comparison of Rap siRNA with scrambled siRNA only was considered priority. For 
further experiments, electroporation would definitely be preferred, since it yielded a 
much better knockdown efficiency than using Lipofectamine. 
It would be convenient to perform these experiments not only with downregulation 
of Rap1A using siRNAs, but also with overexpression using the plasmid constructs. 
Again, this should only be done when the appropriate constructs are generated, since 
the folding and/or processing of the GTPase seem to be disrupted, likely affecting its 
function. This would also require a more efficient transfection, relying in either a 
different protocol or a more manageable cell line. 
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6 Future perspectives 
Although some of the objectives have not been achieved, this work allows the 
establishment of a more appropriate experimental layout. The main challenges to 
reaching the preset goals were the rather inefficient transfection protocols and the fact 
that the protein constructs didn’t behave entirely as expected.  
In further studies, there are at least two options to circumvent the transfection 
efficiency issue: either another protocol should be preferred (reverse transfection, for 
instance) or another cell line that is easier to transfect is used. An attractive candidate 
would be the A549 cell line, which is also a lung epithelial line. The main disadvantage 
over CFBE cells is that A549 cells don’t polarize when grown in filters, therefore not 
being eligible for Ussing chamber experiments or to study cellular differentiation 
processes that depend on cellular polarization; alternatively, CFTR function could be 
studied using iodide efflux assays.  
GFP-tagged small GTPases are not common in the literature. Even though it is a 
small protein, GFP is still bigger than Rap1A, so effects on Rap1A folding, processing 
and interactions with partners are not totally surprising. A smaller tag, like FLAG, on the 
N-terminus would be preferable80. This would require additional rounds of mutagenesis 
and cloning to be performed. Evaluating transfection efficiency would require Western 
Blotting, which is less practical than with a fluorescent tag; however, 
immunofluorescence and immunoprecipitation might be easier to do, as the antibodies 
directed against this kind of tags are usually quite good for either technique. 
Additionally, several experiments remain to be performed. It would be interesting to 
evaluate the impact of Rap1A on CFTR stability at the membrane using modified pulse-
chase approaches, as well as on its endocytosis and recycling rates using biotinylation 
protocols. It would also be interesting to use the Epac-selective cAMP analogue 8-
pCPT-2’-O-Me-cAMP-AM to study how this RapGEF impacts CFTR function (Ussing 
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8.3 Appendix III – Preparation of GST-RalGDS-RBD-coupled beads for 
Rap1A activity assays 
The GST-RalGDS-RBD-coupled beads had to be produced for the Rap1A activity 
assays. Bacteria transformed with the pGEX-GST-RalGDS-RBD were available from 
the start of the work. Recombinant protein expression had previously been shown to be 
maximal after 4 hours of incubation with IPTG.  
To confirm expression of the recombinant protein, aliquots of bacteria were taken 
immediately before and 4h after incubation with IPTG, centrifuged at 4000g for 10min 
and lysed in 1x sample buffer. Extracts were run on an SDS-PAGE gel, which was then 
stained with Coomassie Blue, as can be seen in Figure 8.1. 
 
Figure 8.1 - Coomassie-stained SDS-PAGE gel showing expression of recombinant protein after 
induction with IPTG. 
Recombinant protein expression was confirmed with the appearance of a strong band 
below the 37kDa marker.  
To prepare the beads, it was still necessary to know how much glutathione-coupled 
agarose beads should be added to the bacterial extracts, which required knowing the 
amount of recombinant protein recovered. For this, increasing amounts of BSA were 
run on an SDS-PAGE gel, as well as an aliquot of the extract. The gel was then stained 




Figure 8.2 - SDS-PAGE gel for quantification of expressed GST-RalGDS-RBD. 
BSA band intensities were then quantified and used to make a standard curve, which is 
represented in Figure 8.3. 
 
Figure 8.3 – BSA standard curve for the SDS-PAGE gel used for quantification of recombinant GST-
RalGDS-RBD. 
Finally, this standard curve was used to extrapolate the amount of protein in the 
bacterial extracts based on the respective band intensity on the gel, yielding a value of 
1.82mg of recombinant protein. Since the manufacturer of the beads recommends 1mL 
of slurry for each 5-6mg of protein, 360uL of slurry was added to the extracts, which 
were then washed and stored as described in section 3.2.5. 
y = 3.598.927,45x + 5.671.773,86 
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